# Program 11 Cancer Immunology

> **NIH NIH P30** · DANA-FARBER CANCER INST · 2024 · $27,488

## Abstract

Cancer Immunology Program
Project Summary / Abstract
The mission of the Cancer Immunology Program is to identify mechanisms that regulate the anti-tumor immune
response and translate this information into efficacious immunotherapies for cancer patients. The central
hypothesis of the program is that a deeper understanding of the requirements for effective innate and adaptive
host responses will advance development of treatment strategies that overcome tumor immune escape.
Program members collaborate extensively across all DF/HCC programs and institutions. The Program
supports an active clinical immunotherapy trials program, especially investigator-initiated clinical trials, across
multiple DF/HCC institutions in immune checkpoint blockade, cancer vaccines, immunoregulatory monoclonal
antibodies, and adoptive cellular therapies, including CAR T cells.
The Program’s 116 members (76 primary and 40 secondary) represent all seven DF/HCC institutions and 15
academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $5.8 million in
direct costs from the NCI and $9.8 million from other sponsors. During the current funding period, Program
members published 985 cancer-relevant papers. Of these, 28% were inter-institutional, 16% were intra-
programmatic, and 44% were inter-programmatic collaborations between two or more DF/HCC members. The
breadth of inter-Program interactions speaks to the impact of Cancer Immunology across a large spectrum of
human cancers.
For the next CCSG funding period, the Program’s Specific Aims are to 1) Discover innate and adaptive
mechanisms of response and resistance to efficacious cancer immunotherapies; 2) Develop and test novel
interventions that deepen the impact of cancer immunotherapy; and 3) Define mechanisms of immune-related
adverse events and enhance the safety of cancer immunotherapies. These Aims align closely with the Center
strategic plan and to achieve them Program members will continue to collaborate extensively across DF/HCC
Programs and member institutions. An important associated goal is to train and mentor future leaders in
Cancer Immunology.

## Key facts

- **NIH application ID:** 10768675
- **Project number:** 5P30CA006516-59
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** Kai W Wucherpfennig
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $27,488
- **Award type:** 5
- **Project period:** 1997-03-10 → 2026-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10768675

## Citation

> US National Institutes of Health, RePORTER application 10768675, Program 11 Cancer Immunology (5P30CA006516-59). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10768675. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*